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The rapid synthesis of oxazolines and their
heterogeneous oxidation to oxazoles under ﬂow
conditions†
Steﬀen Glöckner, Duc N. Tran, Richard J. Ingham, Sabine Fenner, Zoe E. Wilson,
Claudio Battilocchio and Steven V. Ley*
A rapid ﬂow synthesis of oxazolines and their oxidation to the corresponding oxazoles is reported. The
oxazolines are prepared at room temperature in a stereospeciﬁc manner, with inversion of stereo-
chemistry, from β-hydroxy amides using Deoxo-Fluor®. The corresponding oxazoles can then be
obtained via a packed reactor containing commercial manganese dioxide.
Introduction
Oxazolines and oxazoles are important biological scaﬀolds
present within many natural products (Fig. 1).1,2 Amongst the
many synthetic approaches towards these structural motifs,
one very useful strategy involves the cyclodehydration of
β-hydroxy amides using reagents such as Burgess’ reagent,3
the Mitsunobu reagent,4 Martin sulfurane,5 Ph2-SO-Tf2O,
6
PPh3-CCl4
7 or by treatment with fluorinating reagents such as
diethylaminosulfur trifluoride (DAST) and Deoxo-Fluor®.8
The oxidative aromatisation of oxazolines to the corres-
ponding oxazoles is typically achieved using 1,8-diazabicyclo-
[5.4.0]undec-7-ene (DBU) and bromotrichloromethane.8,9
Other reagents such as NiO2,
10 CuBr2/DBU,
11 NBS/hv,12 CuBr/
peroxide12 or O2 gas
13 have also been successfully employed,
although largely for the oxidation of C5-unsubstituted oxazo-
line rings. While manganese(IV) dioxide (MnO2) has been
applied with some success to the preparation of thiazoles
from thiazolidines,14 to date it has not been widely used for
the synthesis of oxazoles and only a few examples exist in the
literature.15,16
We have previously described the preparation of oxazolines
in flow during the synthesis of o-methyl siphonazole,9 hennox-
azole A17 and bisoxazoline PyBox chiral ligands.18 DAST was
employed to eﬀect the cyclisation of a β-hydroxy amide to the
oxazoline at 70–90 °C, followed by in-line quenching of
residual HF. This approach greatly improved the safety profile
of the reaction compared to the batch synthesis, as well as pro-
viding pure products without need for additional purification.
With these benefits in mind, it was decided to further investi-
gate the scope of this flow transformation, employing the
more stable Deoxo-Fluor® reagent.
Our experience has shown that manganese dioxide can be
simply packed into an Omnifit® column19 and used success-
fully as a heterogeneous reagent in flow processes, without the
problems usually associated with the use of this reagent in
batch synthesis, i.e. its tendency to adhere to surfaces and
cause blockages.20 Here we report the development of a flow
protocol for the rapid cyclodehydration of a diverse range of
β-hydroxy amides using Deoxo-Fluor® and the oxidative aro-
matisation of the resulting oxazolines to oxazoles using com-
mercial activated and amorphous manganese dioxide.
Results and discussion
Our initial investigations focused on the flow synthesis of ox-
azolines, revealing that the use of a slight excess (1.35 eq.)21 of
Fig. 1 Oxazoline- and oxazole-containing natural products.
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Deoxo-Fluor® resulted in >99% conversion of the β-hydroxy
amides to the oxazolines. The use of higher quantities of fluor-
inating agent led to a large number of unwanted by-products.
Unlike typical batch reactions using Deoxo-Fluor®, which
usually require cooling to −20 °C,8 it was found that in flow
optimal yields were obtained at room temperature, desirably
removing the need for cooling.
In a set of model experiments with amide 1a, where resi-
dence time was kept constant at 1.7 min, greater conversion
was observed as flow rate increased, suggesting that mixing
was a key factor for this reaction (Fig. 2).
A flow rate of 6 mL min−1 gave full conversion to the
desired oxazoline 2a.
Under these conditions, a solution of β-hydroxy amide
(0.25 M) and a solution of Deoxo-Fluor®, each delivered at a
flow rate of 3.00 mL min−1, were combined at a T-piece before
passing into a reactor coil (1/16″ o.d., 1 mm i.d., 10 mL, PFA)
at 25 °C. The exiting stream was combined with an aqueous
sodium bicarbonate solution at a T-mixer (flow rate of 9 mL
min−1) to quench any residual HF and then directed into a
Zaiput liquid–liquid membrane separator.22,23 This device
enabled separation of the two phases at a high combined flow
rate (15 mL min−1), with minimal breakthrough of the
aqueous phase into the organic phase (Scheme 1).
The optimised conditions were successfully applied on a
2 mmol scale to a selection of β-hydroxy amides to obtain the
desired oxazolines in moderate to excellent yields with no
need for further purification (Table 1). Aryl oxazolines 2a–f
were obtained in excellent yields and diastereoselectivities.
The dipeptide derivatives subjected to these conditions (1g, 1h
and 1i) showed excellent reactivities, yielding 92–98% of the
desired oxazolines. Moreover, dicyclisation processes were
possible (2k and 2l) with good yield, although higher flow
rates (10 mL min−1) were required. It was found that the yields
under flow conditions were typically 10% higher than the
corresponding batch system, with the eﬃcient heat transfer
and rapid mixing greatly improving the safety profile when
compared to the batch reaction.8
Such a dependence on the flow rate suggested that the
mixing eﬃciency was a significant factor aﬀecting the rate of
cyclisation. Microfluidics are known to provide a highly
eﬃcient static mixing23–26 and therefore the cyclodehydration
of β-hydroxy amides 1b and 1i was attempted on a 1 µL
(Labtrix Start) microchip (Scheme 2).27 It was found that both
substrates could be cyclodehydrated in excellent yield at room
temperature with residence times around 1 s, further support-
ing the importance of mixing for this process.28
Additionally, we wanted to investigate whether this flow pro-
tocol could be run continuously to aﬀord larger amounts
of material, which is frequently a requirement in synthesis.
A microchip reactor would not be appropriate because whilst
it generates an improved reaction rate, it cannot provide
the same potential throughput as a mesofluidic system.
Preliminary investigations into this were carried out using 30 g
of β-hydroxy amide 1a. A magnetic mixer was introduced
to ensure complete quenching over an extended period as
without this device, residual HF was observed in the
organic stream. We also took the opportunity to test a simple
large-scale gravity separation device (see SI) to recover the
organic phase. Using this specific system, 10.2 g h−1 of 2a
could be generated in a single continuous run over 2 h and
40 min, with 27.2 g of 2a being produced (98% yield)
(Scheme 3).
With flow conditions established for the cyclodehydration,
we turned our attention to the MnO2-mediated oxidative aro-
matisation reaction, using oxazoline 2a as a model substrate.
Previous studies had demonstrated that the solvent and temp-
erature have a strong influence on the general oxidative reactiv-
ity of MnO2.
29–31 Oxazoline 2a (0.5 mmol) in 8 mL of a range
of solvents was passed through a column reactor packed with
activated MnO2
32 (3 g) with an initial flow rate of 100 µL
min−1, which was reduced to 60 µL min−1 after 50 min. The
flow output was directly collected and evaporated (Scheme 4).
Dichloromethane, trifluorotoluene and isopropyl acetate
aﬀorded pure desired product at 40 °C, although in low iso-
lated yield (40%, 20% and 32% respectively). We speculate that
the remaining material has decomposed and is retained in the
MnO2 column. When isopropyl acetate was used as solvent at
lower temperature (0 °C), although less material was lost, the
conversion was poorer and the yield significantly reduced
(31%). Neither acetone or dimethoxy ethane (DME) aﬀorded
full conversion at 40 °C, but after purification aﬀorded higher
yields of the desired product (59% and 63% respectively).
Pleasingly, it was found that by increasing the reaction temp-
Fig. 2 Eﬀect of ﬂow rate on cyclodehydration of 1a to 2a (residence
time = 1.7 min).
Scheme 1 Optimised conditions for the ﬂow synthesis of oxazolines.
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erature to 60 °C with DME as solvent, pure 3a could be isolated
in 79% by simply removing the solvent in vacuo (Table 2).
Under these optimised conditions we were able to process
several 2-aryl-substituted oxazolines to oxazoles with isolated
yields of 50–79% (Scheme 4). Notably, pyridyl (3c) and styryl
(3d) oxazolines were compatible with the process giving 65%
and 50% yields respectively. The mild reaction conditions
allowed oxidation in the presence of an acid labile protecting
group (3e). Desirably, all these oxazoles were obtained in
Table 1 Flow cyclodehydration of β-hydroxy amides using Deoxo-Fluor®
Entrya Substrate Product Isolated yieldb
1 1a 2a 98%
2 1b 2b 98%
3 1c 2c 79%c
4 1d 2d 98%
5 1e 2e 99%
6 1f 2f 95%
7 1g 2g 98%
8 1h 2h 92%
9 1i 2i 95%
10 1j 2j 60%
11 1k 2k 85%d
12 1l 2l 92%d
a Reactions were run on a 2 mmol scale. b Compounds were isolated without purification. c The crude material was passed through a plug of
calcium carbonate/silica in place of an aqueous work up. d Total flow rate = 10 mL min−1 with 2.6 eq. of Deoxo-Fluor®.
Scheme 2 Microchip reaction for the preparation of oxazolines.
Scheme 3 Platform set up for the scale up experiment.
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analytically pure form without any further purification, with
inductively coupled plasma-mass spectrometry (ICP-MS) ana-
lyses showing negligible leaching of MnO2 (less than 10 ppb).
However, when these optimised conditions were applied to
2-alkyl-substituted oxazolines, extensive decomposition of
these substrates to unidentified by-products was observed.
It was suspected that the high reactivity of activated MnO2
could be responsible for this decomposition, so the reaction
was attempted using the less active amorphous MnO2
33 under
otherwise identical conditions. At 60 °C only partial conver-
sion to the desired oxazoles was detected whereas increasing
the temperature at 100 °C led to complete conversion of the
starting material. This allowed access to a range of alkyl substi-
tuted oxazoles in moderate to good yields (Scheme 5), includ-
ing sensitive substrates such as oxetane containing 3j. Notably,
the double oxidation of 4 could be carried out in 83% yield to
aﬀord 5, an intermediate in our recent total synthesis of plan-
tazolicin A and B.34 When the same reaction was attempted in
batch the yield could not be optimised beyond 20%, necessitat-
ing a stepwise synthesis of 5.
When using a flow system, there is the possibility to take
advantage of the ability to perform reactions and processes
under computer control.35 In this case, the addition of an auto-
mation layer enabled up to four reactions using diﬀerent sub-
strates to be performed in sequence, with no manual
intervention required apart from loading the reagents before
starting the procedure. A reactor configuration (Scheme 6) was
devised that incorporated a multi-port switching valve (V1) such
that four separate substrates could be passed through four separ-
ate columns to prevent any cross-contamination between
samples. A secondary valve (V2) enabled the flow stream to be
thoroughly purged between each sample, and prevented cross-
contamination as V1 moved between the diﬀerent positions. The
pre-prepared reagent solutions were drawn from four separate
bottles (selected by V1) and passed through the heated MnO2
columns (1–4). A software protocol created in the Python pro-
gramming language35,36 and running on a Raspberry Pi®
microcomputer37 controlled the individual reactor components
according to a pre-programmed sequence of timed actions, to co-
ordinate the pumps and valves to perform the reactions. Using
this system, a batch of four substrates was processed overnight
(12 h). This demonstrates the ability for automated machine-
assisted systems to save skilled researcher time in the laboratory.
Conclusions
In conclusion, an improved rapid method for the flow syn-
thesis of oxazolines at room temperature has been developed.
A multi-hour continuous flow run illustrates the potential of
this method for the safe large scale production of oxazolines.
It was found that aryl-substituted oxazolines undergo smooth
oxidative aromatisation when simply flowed through a column
of activated MnO2 at 60 °C, with isolated yields between
50–79%. Advantageously, unlike batch protocols, no down-
stream workup or purification was found to be required. The
oxidation step has also been demonstrated to be amenable to
automation which allows the sequential processing of 4
diﬀerent substrates on a single flow platform, with minimal
operator intervention. For the more sensitive 2-alkyl-substi-
tuted oxazolines, it was found that good results could be
achieved using amorphous manganese dioxide at increased
temperature, increasing the scope of this process.
Scheme 5 Flow oxidation of 2-alkyl-oxazolines using amorphous
MnO2.
aDeprotection was observed.
Scheme 4 Flow oxidation of aryl-oxazolines using activated MnO2.
Table 2 Solvent screening for ﬂow MnO2 oxidation
Entry Solvent Temperature Isolated yield
1 Acetone 40 °C 59%a
2 Dichloromethane 40 °C 40%
3 Trifluorotoluene 40 °C 20%
4 Isopropyl acetate 0 °C 31%a
5 Isopropyl acetate 40 °C 52%
6 Dimethoxyethane 40 °C 64%a
7 Dimethoxyethane 60 °C 79%
a Incomplete conversion so required purification.
Paper Organic & Biomolecular Chemistry
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Experimental section
General experimental section
1H-NMR spectra were recorded on a Bruker Avance DPX-400
spectrometer with the residual solvent peak as the internal
reference (CDCl3 = 7.26 ppm, d6-DMSO = 2.50 ppm).
1H reso-
nances are reported to the nearest 0.01 ppm. 13C-NMR spectra
were recorded on the same spectrometers with the central reso-
nance of the solvent peak as the internal reference (CDCl3 =
77.16 ppm, d6-DMSO = 39.52 ppm). All
13C resonances are
reported to the nearest 0.1 ppm. DEPT 135, COSY, HMQC, and
HMBC experiments were used to aid structural determination
and spectral assignment. The multiplicity of 1H signals are
indicated as: s = singlet, d = doublet, t = triplet, m = multiplet,
br. = broad, or combinations of thereof. Coupling constants ( J)
are quoted in Hz and reported to the nearest 0.1 Hz. Where
appropriate, averages of the signals from peaks displaying
multiplicity were used to calculate the value of the coupling
constant. Infrared spectra were recorded neat on a Perkin-
Elmer Spectrum One FT-IR spectrometer using Universal ATR
sampling accessories. Unless stated otherwise, reagents were
obtained from commercial sources and used without purifi-
cation. The removal of solvent under reduced pressure was
carried out on a standard rotary evaporator. Melting points
were performed on either a Stanford Research Systems
MPA100 (OptiMelt) automated melting point system and are
uncorrected. High resolution mass spectrometry (HRMS) was
performed using a Waters Micromass LCT Premier™ spectro-
meter using time of flight with positive ESI, or conducted by
Mr Paul Skelton on a Bruker BioApex 47e FTICR spectrometer
using (positive or negative) ESI or EI at 70 eV to within a toler-
ance of 5 ppm of the theoretically calculated value. LC-MS
analysis was performed on an Agilent HP 1100 series
chromatography (Mercury Luna 3u C18 (2) column) attached
to a Waters ZQ2000 mass spectrometer with ESCi ionization
source in ESI mode. Elution was carried out at a flow rate
of 0.6 mL min−1 using a reverse phase gradient of acetonitrile
and water containing 0.1% formic acid. Retention time (Rt)
is given in min to the nearest 0.1 min and the m/z value
is reported to the nearest mass unit (m.u.). Specific
optical rotation was recorded on a Perkin-Elmer Model 343
digital polarimeter, using a Na/Hal lamp set at 589 nm and
with a path length of 100 mm. All [α]D values were measured
using spectroscopy grade solvent at the specified concentration
and temperature. Unless otherwise specified all the flow
reactions were performed using a Vapourtec R2/R4+ flow
platform.38
General protocol for the preparation of oxazoline in flow
A solution of Deoxo-Fluor® (1 mL, 50% in toluene) in CH2Cl2
(7.0 mL) and a solution of β-hydroxy amide (2 mmol) in
CH2Cl2 (8 mL) were combined at a T-piece (each stream run at
3.0 mL min−1) and reacted at rt in a 10 mL PFA reactor coil.
The combined stream was then directed to an aqueous
quenching stream (9 mL min−1) and the solution directed to a
liquid/liquid separator.22
(4S,5S)-5-Methyl-2-phenyl-4,5-dihydro-oxazole-4-carboxylic
acid methyl ester (2a). 1H-NMR (600 MHz, CDCl3) δ =
7.98–7.96 (m, 2H), 7.49–7.46 (m, 1H), 7.40–7.38 (m, 2H), 5.05
(dq, 1H, J = 10.2, 6.4 Hz), 4.97 (d, 1H, J = 10.2 Hz), 3.76 (s, 3H),
1.37 (d, 3H, J = 6.5 Hz); 13C-NMR (151 MHz, CDCl3) δ = 170.5,
166.2, 131.9, 128.6, 128.4, 127.3, 77.7, 71.8, 52.2, 16.3; HR-MS
(ESI+) for C12H14NO3
+ [M + H]+ calc.: 220.0974, found:
220.0981; FT-IR neat, ν˜ (cm−1) = 2953, 1736, 1645, 1603, 1580,
1496, 1450, 1384, 1349, 1244, 1197, 1174, 1067, 1045, 1001,
973, 934, 904, 886, 851, 778, 695; specific rotation: [α]24.1D =
+58.58° cm3 g−1 dm−1 (c = 8.5 in ethanol). Lit.: [α]20D = +69.4°
cm3 g−1 dm−1 (c = 8.5 in EtOH).39
(4S,5S)-2-(4-Chlorophenyl)-5-methyl-4,5-dihydrooxazole-4-carb-
oxylic acid methyl ester (2b). 1H-NMR (600 MHz, CDCl3) δ =
Scheme 6 Automated oxidation of oxazolines using a Raspberry Pi® computer and a multiple position valve.
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7.90 (d, 2H, J = 8.3 Hz), 7.37 (d, 2H, J = 8.4 Hz), 5.05 (m, 1H),
4.96 (d, 1H, J = 10.2 Hz), 3.76 (s, 3H), 1.36 (d, 3H, J = 6.5 Hz);
13C-NMR (151 MHz, CDCl3) δ = 170.3, 165.4, 138.1, 130.0,
128.7, 125.8, 78.0, 71.8, 52.2, 16.3; HR-MS (ESI+) for
C12H13ClNO3
+ [M + H]+ calc.: 254.0584, found: 254.0575; FT-IR
neat, ν˜ (cm−1) = 2953, 1737, 1646, 1599, 1491, 1437, 1404,
1384, 1355, 1244, 1197, 1172, 1091, 1075, 1045, 1015, 935, 904,
887, 840, 780, 731, 680; specific rotation: [α]24.0D = +48.2° cm
3
g−1 dm−1 (c = 1 in CHCl3).
(4S,5S)-5-Methyl-2-(pyridin-3-yl)-4,5-dihydrooxazole-4-carb-
oxylic acid methyl ester (2c). 1H-NMR (600 MHz, CDCl3) δ =
9.14–9.13 (m, 1H), 8.69 (dd, 1H, J = 4.9, 1.7 Hz), 8.24–8.22 (m,
1H), 7.33 (ddd, 1H, J = 7.9, 4.9, 0.8 Hz), 5.07 (dq, 1H, J = 10.2,
6.5 Hz), 4.97 (d, 1H, J = 10.2 Hz), 3.75 (s, 3H), 1.37 (d, 3H, J =
6.5 Hz); 13C-NMR (151 MHz, CDCl3) δ = 170.1, 164.3, 152.5,
149.8, 136.0, 123.5, 123.3, 78.1, 71.7, 52.3, 16.3; HR-MS (ESI+)
for C11H13N2O3
+ [M + H]+ calc.: 221.0926, found: 221.0926;
FT-IR neat, ν˜ (cm−1) = 2953, 1743, 1650, 1593, 1432, 1417,
1353, 1246, 1198, 1176, 1082, 1044, 1023, 936, 905, 886, 821,
781, 708, 620; specific rotation: [α]24.0D = +53.0° cm
3 g−1 dm−1
(c = 1 in CHCl3).
(4S,5S)-5-Methyl-2-((E)-styryl)-4,5-dihydrooxazole-4-carboxylic
acid methyl ester (2d). 1H-NMR (600 MHz, CDCl3) δ = 7.43 (d,
2H, J = 7.5 Hz), 7.38 (d, 1H, J = 16.3 Hz), 7.32–7.27 (m, 3H),
6.65 (d, 1H, J = 16.3 Hz), 4.92 (dq, 1H, J = 10.1, 6.3 Hz), 4.87 (d,
1H, J = 10.0 Hz), 3.70 (s, 3H), 1.30 (d, 3H, J = 6.5 Hz); 13C-NMR
(151 MHz, CDCl3) δ = 170.0, 165.6, 140.8, 134.7, 129.5, 128.6,
127.3, 114.6, 77.1, 71.3, 51.8, 16.0; HR-MS (ESI+) for
C14H16NO3
+ [M + H]+ calc.: 264.1236, found: 264.1227; FT-IR
neat, ν˜ (cm−1) = 2951, 1735, 1652, 1607, 1496, 1449, 1358,
1242, 1197, 1174, 1045, 972, 948, 930, 840, 758, 732, 692;
specific rotation: [α]24.0D = +27.9° cm
3 g−1 dm−1 (c = 1 in
CHCl3).
(4S,5S)-2-(2-((4S,5R)-3-(tert-Butoxycarbonyl)-2,2,5-trimethyl-
oxazolidin-4-yl)thiazol-4-yl)-5-methyl-4,5-dihydrooxazole-4-carb-
oxylic acid methyl ester (2e). 1H-NMR (400 MHz, CDCl3) δ =
8.03 (s, 1H), 5.10–5.05 (m, 1H), 4.99 (s, 1H), 4.87–4.74 (s, 1H),
4.25–4.14 (m, 1H), 3.76 (s, 3H), 1.69 (s, 6H), 1.43 (s, 9H), 1.20
(s, 6H); 13C-NMR (100 MHz, CDCl3) δ = 173.9, 170.1, 161.5,
151.5, 143.4, 124.2, 95.37, 80.9, 78.5, 78.0, 71.8, 66.0, 52.2,
28.2, 26.6, 26.1, 18.1, 16.2. HR-MS (ESI+) for C20H30N3O6S
+
(M + H)+ calc.: 440.1855, found: 440.1844. FT-IR neat,
ν˜ (cm−1) = 2977, 1753, 1740, 1704, 1649, 1538, 1453, 1361,
1337, 1303, 1261, 1213, 1177, 1132, 1088, 1066, 1047, 982, 957,
918, 897, 878, 855, 835, 776, 755, 725; specific rotation:
[α]23.9D = −7.4° cm3 g−1 dm−1 (c = 1 in CHCl3).
(S)-2-Phenyl-4,5-dihydrooxazole-4-carboxylic acid methyl
ester (2f). 1H-NMR (400 MHz, CDCl3) δ = 7.98 (d, 2H, J =
7.5 Hz), 7.49 (m, 1H), 7.41 (m, 2H), 4.97 (m, 1H), 4.69 (m, 1H),
4.58 (m, 1H), 3.82 (s, 3H) ppm. Data match those reported in:
A. I. Meyers and F. X. Tavares, J. Org. Chem., 1996, 61,
8207–8215.
(S)-2-((1S,2S)-1-((tert-Butoxycarbonyl)amino)-2-methylbutyl)-
4,5-dihydrooxazole-4-carboxylic acid methyl ester (2g).
1H-NMR (400 MHz, CDCl3) δ = 5.20 (d, 1H, J = 9.0 Hz), 4.75 (m,
1H), 4.52 (t, 1H, J = 8.5 Hz), 4.45 (dd, 1H, J = 10.5, 9.4 Hz), 4.39
(dd, 1H, J = 8.6, 4.4 Hz), 3.77 (s, 3H), 1.84 (s, 1H), 1.50 (m, 1H),
1.43 (s, 9H), 1.15 (m, 1H), 0.89–0.94 (m, 6H) ppm. Data match
those reported in: S. Peña, L. Scarone, E. Manta, L. Stewart,
V. Yardley, S. Croft and G. Serra, Bioorg. Med. Chem. Lett., 2012,
12, 4994–4997.
(S)-2-((S)-1-((tert-Butoxycarbonyl)amino)ethyl)-4,5-dihydroox-
azole-4-carboxylic acid methyl ester (2h). 1H-NMR (400 MHz,
CDCl3) δ = 5.30 (1H, s), 4.95 (m, 1H), 4.79 (dd, 1H, J = 10.0, 1.5
Hz), 4.44 (m, 1H), 3.76 (s, 3H), 1.50–1.40 (m, 10H), 1.28 (d, 3H,
J = 6.5 Hz) ppm. Data match those reported in: Z. Xia and
C. D. Smith, J. Org. Chem., 2001, 66, 3459–3466.
(S)-2-((S)-1-((tert-Butoxycarbonyl)amino)-2-methylpropyl)-4,5-
dihydrooxazole-4-carboxylic acid methyl ester (2i). 1H-NMR
(400 MHz, CDCl3) δ = 5.18 (d, 1H, J = 8.9 Hz), 4.74 (m, 1H),
4.51 (t, 1H, J = 8.7 Hz), 4.43 (dd, 1H, J = 10.3, 8.7 Hz), 4.33 (dd,
1H, J = 8.7, 4.0 Hz), 3.70 (s, 3H), 2.10 (m, 1H), 1.43 (s, 9H), 0.95
(d, 3H, J = 7.0 Hz), 0.90 (d, 3H, J = 6.8 Hz) ppm. Data match
those reported in: A. I. Meyers and F. X. Tavares, J. Org. Chem.,
1996, 61, 8207–8215.
(4S,5S)-5-Methyl-2-(3-methyloxetan-3-yl)-4,5-dihydrooxazole-
4-carboxylic acid methyl ester (2j). 1H-NMR (600 MHz, CDCl3)
δ = 4.99 (d, 1H, J = 5.8 Hz), 4.98–4.93 (m, 1H), 4.95 (d, 1H, J =
5.8 Hz), 4.82 (d, 1H, J = 10.1 Hz), 4.45 (d, 1H, J = 5.8 Hz), 4.44
(d, 1H, J = 5.8 Hz), 3.76 (s, 3H), 1.66 (s, 3H), 1.30 (d, 3H, J =
6.5 Hz); 13C-NMR (151 MHz, CDCl3) δ = 172.1, 170.2, 80.1,
80.0, 78.3, 71.5, 52.3, 39.6, 22.3, 16.2; HR-MS (ESI+) for
C10H16NO4
+ [M + H]+ calc.: 214.1079, found: 214.1076; FT-IR
neat, ν˜ (cm−1) = 2926, 1738, 1658, 1450, 1361, 1255, 1198,
1175, 1133, 1044, 982, 945, 844, 781, 732; specific rotation:
[α]23.9D = +47.2° cm
3 g−1 dm−1 (c = 1 in CHCl3).
(4R,4′S,5S,5′S)-2′-((1S,2S)-1-((tert-Butoxycarbonyl)amino)-2-
methylbutyl)-5,5′-dimethyl-4,4′,5,5′-tetrahydro-[2,4′-bioxazole]-
4-carboxylic methyl ester (2k). 1H NMR (600 MHz, CDCl3) δ =
7.58 (s, 1H), 6.57–6.39 (m, 1H), 5.14 (d, J = 7.5 Hz, 1H), 4.92 (s,
1H), 4.77 (d, J = 10.0 Hz, 1H), 4.08 (d, J = 7.1 Hz, 1H), 3.70 (s,
3H), 1.92 (s, 1H), 1.72 (d, J = 7.2 Hz, 3H), 1.52 (d, J = 17.1 Hz,
1H), 1.45–1.36 (m, 21H), 1.25 (d, J = 6.5 Hz, 3H), 1.13 (d, J =
20.7 Hz, 1H), 0.95 (d, J = 6.9 Hz, 3H), 0.87 (t, J = 7.4 Hz, 4H);
13C NMR (151 MHz, CDCl3) δ = 170.0, 169.8, 164.2, 155.7,
130.8, 122.8, 79.8, 78.3, 71.2, 59.5, 51.9, 37.3, 28.2, 24.6, 16.0,
15.7, 14.8, 11.5; HR-MS (ESI+) for C20H34N3O6
+ (M + H)+ calc.:
412.2448, found.: 412.2442; FT-IR neat, ν˜ (cm−1) = 3342, 3256,
2967, 1740, 1687, 1658, 1626, 1521, 1454, 1390, 1365,
1288, 1240, 1200, 1170, 1042, 1019, 870, 777; specific rotation:
[α]26.0D = +19.7° cm
3 g−1 dm−1 (c = 1 in CHCl3).
2,6-Bis((R)-4-Phenyl-4,5-dihydrooxazol-2-yl)pyridine (2l).
1H-NMR (400 MHz, CDCl3) δ = 8.36 (d, 2H, J = 7.8 Hz), 7.93 (t,
1H, J = 7.8 Hz), 7.40–7.29 (m, 10H), 5.48 (dd, 2H, J = 10.2,
8.7 Hz), 4.94 (dd, 2H, J = 8.7, 10.4 Hz), 4.44 (t, 2H, J = 8.9 Hz)
ppm. Data match those reported in: P. C. Knipea and
M. D. Smith, Org. Biomol. Chem., 2014, 12, 5094–5097.
General protocol for the preparation of 2-aryl-oxazoles in flow
A solution of oxazoline (0.5 mmol) in DME (8 mL) was passed
through a column reactor packed with activated MnO2 at 60 °C
(flow rate 100 µL min−1 for 50 min then 60 µL min−1). The
Paper Organic & Biomolecular Chemistry
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machine output was collected and concentrated under vacuum
to give the corresponding oxazoles in good yield, without the
need of further purification.
2-Phenyl-5-methyloxazole-4-carboxylic acid methyl ester
(3a). 1H-NMR (400 MHz, CDCl3) δ = 8.03 (m, 2H), 7.42 (m,
3H), 3.91 (s, 3H), 2.68 (s, 3H) ppm. Data matched those
reported in: G. Yuan, Z. Zhu, X. Gao and H. Jiang, RSC Adv.,
2014, 4, 24300–24303.
2-(4-Chlorophenyl)-5-methyloxazole-4-carboxylic acid methyl
ester (3b). White solid, m.p. 102–104 °C; 1H-NMR (400 MHz,
CDCl3) δ = ppm 7.99–8.02 (m, 2H), 7.42–7.45 (m, 2H), 3.95 (s,
3H), 2.71 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ = 162.7, 158.8,
156.6, 137.0, 129.1, 128.7, 127.8, 125.0, 52.1, 12.1 ppm; HR-MS
(ESI+) for C12H11NClO3
+ [M + H]+ calc.: 252.0427, found:
252.0422; FT-IR neat, ν˜ (cm−1) = 3001, 2950, 2857, 1717, 1614,
1585, 1559, 1485, 1450, 1346, 1278, 1235, 1109, 1090, 1056,
1011, 827, 726, 692.
5-Methyl-2-(pyridin-3-yl)oxazole-4-carboxylic acid methyl
ester (3c). Yellowish solid, m.p. 62–70 °C; 1H-NMR (400 MHz,
CDCl3) δ = 9.27 (d, 1H, J = 1.5 Hz), 8.69 (dd, 1H, J = 4.8, J =
1.5 Hz), 8.35 (dt, 1H, J = 8.3, J = 1.9 Hz), 7.38–7.42 (m, 1H),
3.95 (s, 3H), 2.73 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ = 162.5,
157.3, 151.4, 147.6, 133.8, 128.8, 127.8, 123.6, 122.9, 52.2,
12.1 ppm; HR-MS (ESI+) for C11H11N2O3
+ [M + H]+ calc.:
219.0770, found: 219.0779; FT-IR: neat, ν˜ (cm−1) = 3011, 2953,
1713, 1614, 1577, 1483, 1431, 1418, 1386, 1347, 1235, 1197,
1109, 1071, 1018, 979, 820, 783, 719, 703.
(E)-5-Methyl-2-styryloxazole-4-carboxylic acid methyl ester
(3d). White solid, m.p. 86–88 °C; 1H-NMR (400 MHz, CDCl3) δ
= 7.50–7.56 (m, 3H), 7.37–7.41 (m, 2H), 7.33–7.37 (m, 1H), 6.90
(d, J = 16.5 Hz), 3.93 (s, 3H), 2.68 ppm (s, 3H) ppm; 13C-NMR
(126 MHz, CDCl3) δ = 162.7, 159.4, 156.1, 137.1, 135.2, 129.4,
128.9, 127.2, 113.1, 52.0, 12.1 ppm; HR-MS (ESI+) for
C14H14NO3
+ [M + H]+ calc.: 244.0968, found: 244.0961; FT-IR
neat, ν˜ (cm−1) 2954, 1715, 1644, 1544, 1438, 1388, 1367, 1220,
1180, 1102, 988, 965, 757.
2-(2-((4S,5R)-3-(tert-Butoxycarbonyl)-2,2,5-trimethyloxazolidin-
4-yl)thiazol-4-yl)-5-methyloxazole-4-carboxylic acid methyl
ester (3e). 1H-NMR (400 MHz, CDCl3) δ = 8.11 (br. s., 1H), 4.82
(br. s., 1H), 4.21 (d, 1H, J = 6.3 Hz), 3.95 (s, 3H), 2.74 (s, 3H),
1.72 (br. s., 6H), 1.41–1.55 (m, 6H), 1.13–1.24 (m, 6H) ppm; 13C
NMR (126 MHz, CDCl3) [conformers] δ = 174.2, 170.1, 162.6,
156.6, 155.0, 142.3, 130.2, 129.2, 128.4, 120.4, 95.3, 80.8, 77.8,
66.0, 52.1, 28.1, 26.5, 25.9, 17.8, 12.2; HRMS (ESI+) for
[M + Na]+ C20H27N3O6SNa
+ calc.: 460.1518; found: 460.1501;
FT-IR neat, ν˜ (cm−1) 2977, 2364, 1706, 1616, 1443, 1365, 1262,
1175, 1106, 984, 855, 731.
2-Phenyloxazole-4-carboxylic acid methyl ester (3f). 1H-NMR
(400 MHz, CDCl3) δ = 8.30 (s, 1H), 8.11–8.13 (m, 2H), 7.55–7.45
(m, 3H), 3.96 (s, 3H) ppm. Data match those reported
in: A. I. Meyers and F. X. Tavares, J. Org. Chem., 1996, 61,
8207–8215.
General protocol for the preparation of 2-alkyl-oxazoles in flow
A solution of oxazoline (0.125 mmol) in DME (2 mL) was
loaded into a 2 mL loop and then passed through a column
reactor packed with activated MnO2 at 100 °C (flow rate 100 µL
min−1 for 50 min then 60 µL min−1). Unless otherwise stated,
the machine output was collected and concentrated under
vacuum to give the corresponding oxazoles.
2-((1S,2S)-1-((tert-Butoxycarbonyl)amino)-2-methylbutyl)oxazole-
4-carboxylic acid methyl ester (3g). 1H-NMR (CDCl3, 400 MHz)
δ = 8.17 (s, 1H), 5.30 (d, J = 7.7 Hz, 1H), 4.89–4.80 (m, 1H), 3.90
(s, 3H), 2.00–1.87 (m, 1H), 1.51–1.31 (m, 10H), 1.17 (m, 1H),
0.90–0.85 (m, 6H); 13C-NMR (CDCl3, 100 MHz): δ = 165.1,
161.6, 155.2, 143.7, 133.2, 80.0, 53.3, 52.2, 39.5, 28.3, 25.0,
15.1, 11.3; HRMS (ESI+) for [M + H]+ C15H25N2O5 calculated
313.1758, found 313.1750; FT-IR neat, ν˜ (cm−1) 3323, 2972,
1728, 1698, 1530, 1328, 1232, 1152, 1105; specific rotation:
[α]28.3D = −26.2 cm3 g−1 dm−1 (c = 1 in CHCl3).
(S)-2-(1-Aminoethyl)-5-methyloxazole-4-carboxylic acid methyl
ester (3h). 1H-NMR (400 MHz, CDCl3) δ = 5.02 (q, 1H, J =
6.2 Hz), 3.91 (s, 3H), 2.68 (s, 3H), 1.36 (d, 3H, J = 6.3 Hz) ppm.
Data match those reported in: A. I. Meyers and F. X. Tavares,
J. Org. Chem., 1996, 61, 8207–8215.
(S)-2-(1-((tert-Butoxycarbonyl)amino)-2-methylpropyl)oxazole-
4-carboxylic acid methyl ester (3i). 1H-NMR (400 MHz, CDCl3)
δ = 5.28 (d, 1H, J = 8.8 Hz), 4.80 (dd, 1H, J = 8.8, 6.2 Hz), 3.92
(s, 3H), 2.19 (m, 1H), 1.43 (s, 9H), 0.93 (d, 3H, J = 7.0 Hz), 0.91
(d, 3H, J = 6.8 Hz) ppm. Data matched those reported in:
A. Bertram and G. Pattenden, Heterocycles, 2002, 58, 521–561.
5-Methyl-2-(3-methyloxetan-3-yl)oxazole-4-carboxylic acid
methyl ester (3j). 1H-NMR (400 MHz, CDCl3) δ = 5.06 (d, 2H,
J = 5.9 Hz), 4.53 (d, J = 5.9 Hz, 2H), 3.89 (s, 3H), 2.62 (s, 3H),
1.79 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 164.0, 162.7,
156.7, 127.4, 80.5, 52.0, 39.6, 22.8, 12.0; HR-MS (ESI+) for
C10H14NO4
+ [M + H]+ calc.: 212.0917, found: 212.0913; FT-IR
neat, ν˜ (cm−1) 2956, 2880, 1719, 1668, 1621, 1585, 1441, 1350,
1250, 1180, 1132, 1090, 980, 787.
2′-((1S,2S)-1-((tert-Butoxycarbonyl)amino)-2-methylbutyl)-[2,4′-
bioxazole]-4-carboxylic acid methyl ester (5). 1H-NMR (CDCl3,
400 MHz) δ = 8.30 (s, 1H), 8.29 (s, 1H), 5.30 (d, J = 9.1 Hz, 1H),
4.90 (dd, J = 9.2, 5.8 Hz, 1H), 3.94 (s, 3H), 2.02–1.92 (m, 1H),
1.47–1.40 (m, 10H), 1.43 (m, 1H), 0.90–0.80 (m, 6H); 13C-NMR
(CDCl3, 100 MHz) δ = 165.5, 161.3, 155.7, 155.2, 143.7, 139.3,
134.3, 129.6, 80.1, 53.4, 52.3, 39.5, 28.3, 25.1, 15.2, 11.4; HRMS
(ESI) for C18H25N3O6Na
+ [M + Na]+ calculated: 402.1636;
found: 402.1629; FT-IR neat, ν˜ (cm−1) 3141, 2959, 1721, 1690,
1509, 1247, 1147, 1001, 870, 729; specific rotation: [α]D25.0 =
−34.0 cm3 g−1 dm−1 (c = 1 in CHCl3).
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